By synthesizing current knowledge and providing new insights into GLP-1-RA-dependent treatments for metabolic disorders and obesity, this study seeks to contribute to the evolving landscape of metabolic health management. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.